Pignata, S., Cecere, S. C., & Di Maio, M. (2016). Bevacizumab as first-line treatment of ovarian cancer: strengths and weaknesses of subgroup analyses:  . Cancer Breaking News, 4(1), 45–47. https://doi.org/10.19156/cbn.2016.0009